FilingSEC EDGAR8-K
Vyome Holdings Reports Q2 2026 Results and Clinical Program Update
· SEC accepted
StagePhase 2
Filing content
Vyome Holdings reported its financial results for the second quarter of 2026 and provided an update on its lead clinical program, VT-1953, noting ongoing engagement with the FDA.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…